Compound research hub

CJC-1295 with DAC: Research, Handling and Batch Documentation

CJC-1295 with DAC is a GHRH analogue carrying a Drug Affinity Complex that binds serum albumin, which is what separates its multi-day half-life from the minutes of unmodified GHRH.

Part of Volta's growth hormone research peptides catalogue.

Identity and research status

Also referred to as: CJC-1295 DAC, CJC-1295 with Drug Affinity Complex, DAC:GRF
Backbone: Human GHRH(1-29) with four amino acid substitutions
Key Substitution: D-alanine at position 2, blocking DPP-4 cleavage
Conjugation Group: Maleimidopropionyl Drug Affinity Complex at the C-terminal lysine
Albumin Binding: Covalent, via reaction with a free cysteine thiol on serum albumin
Molecular Weight: Approximately 3647 g/mol for the unconjugated peptide
CAS Number: 863288-34-0
Also Known As: DAC:GRF, CJC-1295 DAC
Half-life: Reported on the order of 6 to 8 days
Receptor Target: GHRH receptor on pituitary somatotrophs
Appearance: White lyophilised powder

Evidence level: Phase I-II data; research compound (grade C)

Regulatory status: Research compound. Phase 1/2 clinical data exists (ConjuChem). Not approved for any indication.

Evidence grades describe the published literature on the compound, not a property of the material Volta supplies, and are not a statement that any use is approved. See how these grades are assigned.

Mechanism, in brief

CJC-1295 with DAC is a modified growth hormone releasing hormone analogue built on the GHRH(1-29) backbone, carrying four amino acid substitutions and, critically, a maleimidopropionyl group known as the Drug Affinity Complex. The four substitutions protect the peptide from enzymatic degradation, beginning with D-alanine at position 2, which blocks the dipeptidyl peptidase-4 cleavage that makes unmodified sermorelin short-acting.

Enzymatic protection. Four substitutions on the GHRH(1-29) backbone, including D-alanine at position 2, block dipeptidyl peptidase-4 cleavage of the region required for receptor activation.
Covalent albumin conjugation. The maleimidopropionyl DAC group reacts with a free cysteine thiol on albumin to form a covalent bond, unlike the reversible fatty acid binding used by acylated incretin analogues.
Extended circulation. Covalent attachment to albumin gives a half-life reported on the order of six to eight days, producing sustained rather than pulsatile exposure.
GHRH receptor agonism. Agonism at the GHRH receptor on pituitary somatotrophs, signalling through Gs and cyclic AMP to trigger growth hormone release and synthesis.
Sustained IGF-1 elevation. The clinical study reported prolonged elevation of both growth hormone and insulin-like growth factor 1, which is the measurable consequence of continuous rather than pulsed receptor stimulation.

The full research write-up, including the findings behind each claim and the model each came from, is on the CJC-1295 DAC 5mg 5mg page.

Vial sizes available

Every size of CJC-1295 with DAC Volta lists, in stock or not. Each is a separate catalogue page with its own batch number and specification table.

CJC-1295 DAC 5mg 5mgBatch #: VPCD5100
Restocking

Purity and batch documentation

Volta's release specification is >99% (HPLC). That is a threshold we set. >99% is the specification every batch is released to. The figure on a certificate is what a laboratory measured for one lot.

No third-party certificate has been published for CJC-1295 with DACyet. The certificates Volta does publish, with the laboratory's own verification link on each, are in the certificate archive.

the complete batch history dataset how each batch is tested laboratories that test peptides independently

Research on CJC-1295 with DAC

Concentrations used in the literature

the concentrations used in published CJC-1295 with DAC work

Comparisons

Studied alongside other compounds

the GHRH-plus-secretagogue pairing in the literature

Class guide

the growth hormone secretagogue class guide

Handling and stability

Laboratory guides

Calculators

Regulatory context

United States: Not FDA-approved. Research compound only.
Canada: Not approved by Health Canada.
European Union: Not EMA-approved.

Primary sources

Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism (2006). PMID 16352683
Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance. Journal of Clinical Endocrinology and Metabolism (1994). PMID 7962295
Dominikowski A, Rękoś Z, et al.. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Frontiers in Endocrinology (2026). PMID 42395176
Mendias CL, Awan TM, et al.. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries. Sports Medicine (2026). PMID 41966639
Villegas Meza AD, Nocek M, et al.. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence and Safety. JBJS Reviews (2026). PMID 42160466
Renke G, Chinellato L, et al.. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety and Clinical Applications. International Journal of Molecular Sciences (2026). PMID 42123471

More growth hormone research peptides

CJC-1295 with DAC sits in Volta's growth hormone research peptides catalogue, alongside the other compounds studied in this area. The whole range is on the full research catalogue, and the library of comparisons and guides is under peptide research.